11th Annual Western AF Symposium Agenda
Each year great advancements in Atrial fibrillation research help to further the medical field and improve our patient’s treatment and quality of life. Enjoy discussion panels and listen to some of the top AF leaders and physicians at the 11th annual WAF Symposium. View the 2018 AF Symposium schedule for the 23-24th of February.
Friday, February 23, 2018
|6:45 am ||Registration & Breakfast|
|7:15 am ||Welcome
Nassir Marrouche, MD
Kevin Campbell, MD; John Mandrola, MD
Chairs: Melvin Scheinman, MD; Fred Han, MD
|7:30 am||Is AF ablation safer than AAD? A systematic review
John P. DiMarco, MD, PhD
|7:45 am||Interaction between hypercoagulability and atrial fibrillation
Ulrich Schotten, MD, PhD
|8:00 am||Clinical outcomes of AF mapping and rotor guided ablation
David Wilber, MD
|8:15 am||LAA closure: Long-term follow-up data
Rahul N. Doshi, MD
|8:30 am||Predisposition gene discovery in Utah: Atrial fibrillation and fibrosis
Lisa Cannon-Albright, PhD
Chairs: David Wilber, MD; Roger Freedman, MD
|9:00 am||It is all about lesion delivery: Is electroporation the future of AF ablation?
Pierre Jais, MD
|9:15 am||Atrial MR imaging: How to improve resolution?
Dana C. Peters, PhD
|9:30 am||LAA closure devices: Benefit beyond stroke prevention?
Dhanunjaya Lakkireddy, MD
|9:45 am||Is AF a marker or a risk for stroke?
Nazem Akoum, MD, MS
Chairs: Jonathan Piccini, MD; Melvin Scheinman, MD
|10:30 am||Is AF ablation a first-line therapy in 2018?
Eric Prystowsky, MD
|10:45 am||CABANA: What to expect?
Douglas Packer, MD
|11:00 am||Is atrial fibrosis reversible: Insights from experimental evidence
Stanley Nattel, MD
|11:15 am||QoL post AF ablation: the CAPTAF trial
Carina Blomström-Lundqvist, MD, PhD
Chairs: Michael Cutler, DO, PhD; Fred Han, MD
|12:30 pm||Cryo-balloon for AF: Long-term results
Bradley Knight, MD
|12:45 pm||Is it AF or the myopathy? Lessons from MR imaging
Saman Nazarian, MD, PhD
|1:00 pm||Atrial fibrosis modeling: Clinical implications
Natalia Trayanova, PhD
|1:15 pm||Mortality benefit post AF ablation: The CASTLE-AF trial
Johannes Brachmann, MD
Chairs: Jonathan Piccini, MD; Roger Freedman, MD
|1:45 pm||Do we still need to monitor for asymptomatic AF after ablation?
Suneet Mittal, MD
|2:00 pm||Rotational activity and atrial fibrosis: How DECAAF II might help?
Christian Sohns, MD
|2:15 pm||Post-ablation blanking period: 4, 8, 12 or zero weeks?
David Callans, MD
|2:30 pm||Catheterized fiber-optics confocal microscopy for mapping of atrial fibrosis
Frank B. Sachse, PhD
Chairs: David Callans, MD; Saman Nazarian, MD, PhD
|3:15 pm||Targeting rotational activity during re-do procedures
Sanjiv M. Narayan, MD, PhD
|3:30 pm||CASTLE-AF: What we learned beyond the primary endpoint
Nassir Marrouche, MD
|3:45 pm||Treatment of esophageal injury post AF ablation: A GI perspective
Deborah Fisher, MD, MHS
|4:00 pm||AF in heart failure patients: Lessons from SCD-HeFT
Jeanne Poole, MD
Chairs: Frank B. Sachse, PhD; Suneet Mittal, MD
|4:30 pm|| Esophageal protection during AF ablation
Moussa C. Mansour, MD
|4:45 pm||When to anticoagulate AF patients with CHA2DS2-VASc <2?
Andrea M. Russo, MD
|5:00 pm||Risk factors for AF in women
Christine Albert, MD, MPH
Moderators: Walid Saliba, MD; Darryl S. Wells, MD
|5:35 pm||Roundtable: How, when and why to monitor for AF—Examples from practice
Andres Bochoeyer, MD; Bengt Herweg, MD; Nischala Nannapaneni, MD; Kamran Rizvi, MD; T. Scott Wall, MD; Bassam Wanna, MD
Saturday, February 24, 2018
|6:45 am ||Registration & Breakfast
Chairs: John Mandrola, MD; Alexies Ramirez, MD
|7:15 am||Real-world impact of NOACs: Neurologist perspective
Scott Brehaut, MD
|7:30 am||ESC AF guidelines update
Gerhard Hindricks, MD, PhD
|7:45 am||How much AF is too much? (Especially with wearables everywhere…)
Mintu Turakhia, MD
|8:00 am||Debate: DOACs should be given for at least 6 weeks post-LAA implant
Pro: Jonathan Lowy, MD
Con: Julian Chun, MD
Chairs: Fred Han, MD; Julian Chun, MD
|8:30 am||Contemporary real-world and registry data of NOACs: Is Coumadin dead?
Jonathan Hsu, MD, MAS
|8:45 am||Low-voltage zone vs MR detected fibrosis: A comparison
Takanorai Yamaguchi, MD
|9:00 am||Why are we struggling to agree on an ideal mapping system for AF?
Olaf Döessel, PhD
|9:15 am||Ablation of AF: 10 years of follow-up
Andrea Natale, MD
Chairs: Prash Sanders, MBBS, PhD; Thomas J. McGarry, MD, PhD
|10:00 am||AF & OSA: Chicken and the egg
Thomas F. Deering, MD, MBA
|10:15 am||Cardiac fibrosis and treatment outcome: Lessons from CAMERA-MRI
Jonathan M. Kalman, MBBS, PhD
|10:30 am||A novel AF risk scoring model using MRI
Brent D. Wilson, MD, PhD
|10:45 am||High-power, short-duration lesions during AF ablation: Lessons from MRI
Mihail G. Chelu, MD, PhD
|11:00 am||MR pulmonary vein scans in AF patients: More to it than just fibrosis
Christopher J. McGann, MD
Chairs: Thomas Deneke, MD; Vikas Sharma, MD
|12:30 pm||Approaches to ablate persistent AF in 2018: Why too many?
Gregory Michaud, MD
|12:45 pm||How to modify lifestyle and educate the AF patient?
Prash Sanders, MBBS, PhD
|1:00 pm||Role of atrial fibrosis during surgical AF ablation
Ralph J. Damiano, Jr., MD
|1:15 pm||How to best monitor treatment with NOACs?
Elaine M. Hylek, MD, MPH
Chairs: Atul Verma, MD; Stephen Rechenmacher, MD
|1:45 pm||Real-time MRI cryo-balloon guided ablation
Evgueni G. Kholmovski, PhD
|2:00 pm||Radiofrequency balloon systems
Amin Al-Ahmad, MD
|2:15 pm||Real-time MRI for cardiac ablation
Philipp Sommer, MD
|2:30 pm||Is transmural lesion an important endpoint during AF ablation? Show me the data!
David Haines, MD
Chairs:Christian Mahnkopf, MD; David Haines, MD
|3:15 pm||Patient-reported outcomes in AF
Benjamin A. Steinberg, MD, MHS
|3:30 pm||Off-label treatment of AF
Kimberly A. Selzman, MD, MPH
|3:45 pm||Importance of durable PVI for persistent AF
Atul Verma, MD
Chairs: Philip Sommer, MD; David Haines, MD
|4:15 pm||Treatment of AF: Heart failure specialist’s perspective
Heribert Schunkert, MD
|4:30 pm||Lessons learned from acute and chronic ablation lesion visualization using MRI
Ravi Ranjan, MD, PhD
|4:45 pm||How early should we ablate AF? Temporal and structural criteria
Oussama Wazni, MD
Moderators: Kevin Campbell, MD; John Mandrola, MD
Mihail G. Chelu, MD, PhD; John D. Day, MD; Christian Mahnkopf, MD; Debbe McCall, MBA; Jonathan Piccini, MD; Mellanie True Hills; Oussama Wazni, MD
*Agenda is subject to change